Divis Laboratories has accepted the retirement of two key senior management executives, L. Ramesh Babu and D. Madhu Babu, marking a leadership transition within its operational hierarchy. The company intimated the National Stock Exchange of India Limited and BSE Limited that both Vice Presidents will cease to be Senior Management Personnel effective from the close of business hours on July 31, 2026. This disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The departure affects two critical functional areas: procurement and projects. L. Ramesh Babu served as Vice President (Procurement), while D. Madhu Babu held the position of Vice President (Projects). Both executives are retiring from their respective roles simultaneously. The company’s Company Secretary & Compliance Officer, M. Satish Choudhury, signed the intimation letter dated July 31, 2026, confirming the cessation of their employment status.

Executive Details

The following table outlines the specific details of the retiring executives as disclosed in the filing:

Regulatory Compliance

The intimation references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The filing confirms that there are no undisclosed relationships between directors regarding these cessations, and no brief profiles were required as this is a retirement rather than an appointment. The company stated that this information is for the records of the stock exchanges.

What This Means for Investors

The simultaneous retirement of two Vice Presidents suggests a planned succession or natural attrition rather than a sudden exodus. For a pharmaceutical manufacturer like Divis Laboratories, stability in procurement and project execution is vital for maintaining supply chain efficiency and capital expenditure timelines. Investors should monitor subsequent filings for the appointment of successors to these roles to ensure continuity in these strategic functions. The absence of any negative qualifiers or mentions of dispute indicates a routine administrative update.

Divi's Laboratories Limited will release its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27), on August 1, 2026. The company has scheduled an earnings conference call for the same day at 14:00 IST to discuss its financial performance with investors and analysts. This disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Earnings Call Details

The management team will address queries regarding the Q1 FY27 results during the conference call. A transcript of the discussion will be available on the company’s website, www.divislabs.com , after the event concludes. Investors are advised to join the call approximately five minutes before the scheduled start time to receive instructions from the operator.

Dial-In Information

Participants can access the call via two methods: Express Join with DiamondPass™ or through standard dial-in numbers. Pre-registration for DiamondPass allows participants to join without waiting for an operator.

Contact Information

For further inquiries, investors may contact the Investor Relations department:

• Mobile: +91 91542 18881
• Phone: +91 40 66966352
• Email: mail@divislabs.com

The registered office of Divi's Laboratories Limited is located at Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India.